Importance Obesity affects approximately 42% of US adults and is associated with increased
rates of type 2 diabetes, hypertension, cardiovascular disease, sleep disorders …

Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …

Background Obesity increases the risk of heart failure with preserved ejection fraction.
Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Importance Obesity affects approximately 19% of women and 14% of men worldwide and is
associated with increased morbidity. Antiobesity medications (AOMs) modify biological …

Background SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and
kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the …

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart
failure cases and has a prevalence that is expected to rise with the growing ageing …

The history of anti-obesity pharmacotherapies is marked by disappointments, often
entangled with societal pressure promoting weight loss and the prevailing conviction that …

Diabetes, a complex multisystem metabolic disorder characterized by hyperglycemia, leads
to complications that reduce quality of life and increase mortality. Diabetes pathophysiology …

Background Heart failure with mildly reduced or preserved ejection fraction (hereafter
referred to as HFpEF) is the most common type of heart failure and is associated with a high …